

Notification of Expiry of Unlisted Options

Melbourne, Australia, 13 October 2022: 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) advises that 2,256,775 unlisted options exercisable at \$0.71 each will expire on 24 October 2022.

The unlisted options were granted as an incentive to various parties who are not related to the Company at the time it was admitted to the official list of ASX on 7 August 2020.

Capital Structure

The updated Capital Structure is set out below:

Quoted Securities	Total number of securities on issue
4DX : ORDINARY FULLY PAID	294,491,837
Unquoted Securities	Total number of securities on issue
4DXAG: OPTION EXPIRING VAR DATES RESTRICTED EX VAR PRICES	12,770,998
4DXAI: OPTION EXPIRING 31-DEC-2024 EX \$0.40	2,000,000
4DXAJ: OPTION EXPIRING 15-MAR-2027 EX \$1.20	2,133,333
4DXAK: OPTION EXPIRING 07-AUG-2024 EX 73C	1,283,794
4DXAO: OPTION EXPIRING 25-JUN-2025 EX \$1.30	1,218,806
4DXAN: OPTION EXPIRING 25-DEC-2024 EX \$2.33	35,232
4DXAM: OPTION EXPIRING 15-MAR-2025 EX \$2.33	14,367
4DXAP: OPTION EXPIRING 01-JUL-2025 EX \$2.60	701,719

-ENDS-

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Melanie Leydin
Company Secretary
companysecretary@4dmedical.com

Media

Julia Maguire
+ 61 419 815 386
julia@thecapitalnetwork.com.au



About 4DMedical

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical Limited was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company focused on delivering the global gold standard in respiratory diagnostics for all lung disorders, including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique and transformative XV Technology™ accurately and quickly scans lung function as the patient breathes, enabling early diagnosis and the monitoring of changes over time.

Our Software-as-a-Service (SaaS) delivered Ventilation Reports provide information and insights far beyond the capabilities of conventional modalities, showing subtle variations in lung function down to the finest details in specific regions of each lung, and with lower exposure to radiation than traditional methods.

Respiratory diagnostics is a US\$31 billion per annum global industry. 4DMedical is disrupting this sector and is committed to providing better information to doctors and patients about lung function.

Better information means better decisions and better outcomes.

Learn more: <https://4dmedical.com>